Rebecca Dielschneider
Office 3H32
Address 10 College Crescent, Otterburne, MB, R0A 1G0
Phone 1-431-815-4265

Rebecca Dielschneider

Associate Professor of Health Sciences

Rebecca Dielschneider was born and raised in Halifax, Nova Scotia. She obtained a Bachelor of Science, Honours, with Co-op in Microbiology and Immunology at Dalhousie University. She worked at the National Microbiology Laboratory and Immunovaccine Technologies Incorporated. Rebecca graduated with a Ph.D. in the Department of Immunology from the University of Manitoba in 2016. She was a student leader, won research and presentations awards, and is one of Manitoba’s Future 40 Under 40.

  • 235.12 Introduction to Biology I (includes lab)
  • 235.13 Introduction to Biology II (includes lab)
  • 239.11 Popular Life Science
  • 235.11 Essentials of Microbiology
  • 235.22 Cell Biology (includes lab)
  • 235.23 Genetics (includes lab)
  • 235.25 Scientific Writing and Communication
  • 235.31 Molecular Methods
  • 235.32 Immunology
  • 235.34 Human Disease
  • 235.41 Pharmacology
  • 235.42 Cancer Biology
  • 232.41 Topics in Health Research

University of Manitoba

Doctor of Philosophy (Ph.D.), Department of Immunology

Dalhousie University

Bachelor of Science Degree (B.Sc.), with Co-op
Department of Microbiology and Immunology
First Class Honours



  • Providence University College, Faculty (since 2016)


  • ImmunoVaccine Technologies Inc. (Halifax, NS), Co-op Research Assistant (2010)
  • National Microbiology Laboratory, Public Health Agency of Canada (Winnipeg, MB), Co-op Research Assistant (2009-2010)

Professional Associations

  • Canadian Scientific and Christian Affiliation (CSCA)
  • Canadian Society of Molecular Biosciences (CMSB)
  • Canadian Society of Immunology (CSI)
  • American Association of Cancer Research (AACR)
  • American Society of Hematology (ASH)

Select Awards

  • 1st Place – CancerCare Manitoba Research Day (2013, 2014, 2016)
  • George D. Smith Award for Research Excellence – Canadian CLL Meeting (2015)
  • Gold Leaf Award for Emerging Leader Award in Biotechnology Research – BIOTECanada (2015)
  • Emerging Leader Award – University of Manitoba (2015)
  • Manitoba’s Future 40 Under 40 – CBC (2015)
  • 2nd Place – Canadian National Three Minute Thesis Competition (2015)
  • 1st Place – University of Manitoba Three Minute Thesis Competition (2015)
  • Gold – National Competition, Canadian Student Health Research Forum (2014)
  • PhD Award (2 years of funding support, renewed) – Research Manitoba (2013, 2015)
  • Academic Excellence – Department of Immunology, University of Manitoba (2013)
  • Masters Award (1 year of funding support) – Canadian Institutes of Health Research (2012)


  • Ph.D. Thesis “Targeting Susceptible Signaling Pathways in Chronic Lymphocytic Leukemia”, 2016
  • B.Sc. Honours Thesis “Oncolysis and Immunomodulation in Ovarian Peritoneal Carcinomatosis”, 2011

Peer Reviewed Articles

  • Dielschneider R. (2021). Vaccine hesitancy: Christian reasons and responses. Perspectives on Science and Christian Faith, 73(1), 4-12.
  • Das S, Dielschneider R, et al. (2018). Antimalarial drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells. Leukemia Research, 70, 79-86.
    doi: 10.1016.j.leukres.2018.06.005.
  • Ma S, Dielschneider RF, et al. (2017). Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PLoS One, 12(8), e0182921.
    doi:  10.1371/journal.pone.0182921.
  • Dielschneider RF, et al. (2017). Lysosomes as oxidative targets for cancer therapy. Oxidative Medicine and Cellular Longevity, 2017, 3749157.
    doi: 10.1155/2017/3749157
  • Mi S, Zhao YY, Dielschneider RF, et al. (2016). An LC/MS/MS method for the simultaneous determination of individual sphingolipid species in B cells. Journal Chromatography B, 1031, 50-60.
    doi: 10.1016/j.jchromb.2016.07.028.
  • Dielschneider R, Eisenstat H, Xiao WY, et al. (2016). Lysosomotropic Agents Selectively Target Chronic Lymphocytic Leukemia Cells Due to Altered Sphingolipid Metabolism. Leukemia, 30(6), 1290-300.
    doi: 10.1038/leu.2016.4.
  • Dielschneider R, Xiao WY, Yoon JY, et al. (2014). Gefitinib targets ZAP-70 expressing chronic lymphocytic leukemia cells and inhibits B cell receptor signaling. Cell Death and Disease, 5, e1439.
    doi: 10.1038/cddis.2014.391.
  • Gujar SA, Clements D, Dielschneider R, et al. (2014). Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumor immunological mechanisms. British Journal of Cancer, 110(1), 83-93.
    doi: 10.1038/bjc.2013.695.
  • Gujar S, Dielschneider R, Clements D, et al. (2013). Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation. Molecular Therapy, 21(2), 338-47.
    doi: 10.1038/mt.2012.228.

Workshops & Presentations